Brian Reed: Eliza, long week — but I need to start with something that genuinely annoyed me, in a productive way.
Eliza Ward: Okay, that's a specific kind of feeling. What happened?
Brian Reed: I was reading the press coverage around CBL-514 — the Caliway Biopharmaceuticals announcement, October 13th — and almost every headline said some version of 'weight loss drug without the weight loss.' And I kept thinking, hang on, that's not even the interesting part. The interesting part is that the placebo group gained fat. Like, nobody lost weight and nobody gained weight on the scale, but one group was quietly accumulating visceral fat the whole time.
Eliza Ward: 5.68% increase in the placebo group. Yeah. That number doesn't make the headline.
Brian Reed: You've been tracking this since it broke. Dr. W. Timothy Garvey from UAB, Yu-Fang Ling from Caliway, presenting CBL-0204 and CBL-0205 at EASD 2026 in Milan — the treatment arm shows 12.01% visceral fat reduction measured by MRI. That's the headline. Is the headline right?
Eliza Ward: The number is right. What the number means is — actually, let me separate these. The reduction happened. The MRI caught it. But the MRI was measuring one cross-section at the L2-to-L3 spinal level, not total visceral fat volume across the abdomen. And this is conference-presented data, not a peer-reviewed publication. So the methodology and safety profile haven't gone through formal review yet.
Brian Reed: No peer review — so what are we actually working with here?
Eliza Ward: A real phase 2 signal that needs a phase 3 trial to mean anything for patients. That's the honest answer.
Brian Reed: But that phase 2 signal — okay, so before we get to whether it holds up, I want to back up one step. Because the thing I keep tripping over is: why does it matter that it's visceral fat specifically? Like, fat is fat, right? That's the assumption baked into every scale in every bathroom in the country.
Eliza Ward: Fat is not fat. That's — actually, that's the whole thing. Imagine two people, same weight, same height, same BMI number. One of them carries most of their fat just under the skin — subcutaneous, sits there, mostly inert. The other carries theirs wrapped around the liver, the pancreas, the intestines. Same number on the scale. Completely different metabolic situation.
Brian Reed: Because the visceral fat is doing something?
Eliza Ward: It's producing inflammatory compounds. It's driving insulin resistance. And it does this independently — wait, that's the part people miss — independently of your total body weight. Dr. Samuel Choi at Aurora Health Care has said flat out that visceral fat is more metabolically harmful than subcutaneous fat. And the mechanism backs that up. BMI captures none of this. BMI is weight divided by height squared. It cannot see where the fat is sitting.
Brian Reed: So there's a person walking around with a normal BMI, normal weight on the scale, and their doctor is telling them they're fine — but they're not.
Eliza Ward: That's called normal-weight visceral obesity. NWVO. And a 2026 paper in Frontiers in Nutrition flagged it specifically as an overlooked risk factor for metabolic liver disease in older adults — people with hypertension and diabetes who would never be flagged by BMI alone.
Brian Reed: Hang on — if that paper dropped in 2026, and this distinction has been in the literature for decades longer than that, why is clinical practice still leading with scale weight and BMI? What's actually keeping that from changing?
Eliza Ward: Infrastructure, mostly. To measure visceral fat properly you need an MRI — which is expensive, not routine, and the CBL-514 trials themselves only measured one cross-section at L2 to L3, not total-body volume. So even the research isn't doing it the hard way. And then there's the billing side. Insurance codes, clinical guidelines, they're all built around BMI because it's cheap and fast. Changing that means — I mean, it means rewriting protocols that took decades to standardize.
Brian Reed: So the biology moved, the evidence is moving, but the clinical machinery is still pointed at the scale.
Eliza Ward: Right, and that gap — between the biology moving and the machinery catching up — is actually where this CBL-514 data sits right now. Because here's what actually bothers me when I slow down and look at what we have.
Brian Reed: The measurement thing? That's what keeps coming up for me.
Eliza Ward: One cross-section. L2 to L3. That's one slice of the spine on an MRI — not total-body visceral fat volume. So when Garvey and Yu-Fang Ling present that 12.01% reduction, they're measuring a proxy for a proxy. And we can't even pin down the between-group difference cleanly — sources are putting it at either 17.69 or 22.21 percentage points. That spread alone should make us pause.
Brian Reed: Wait — the same trial, two different numbers for the same gap?
Eliza Ward: Different reporting across sources, yeah. And that's — I mean, that's partly because this was a conference presentation at EASD Milan, September 28 through October 2, not a peer-reviewed publication. Full methodology hasn't been formally reviewed. Safety data, same thing. We got the headline number on October 13 when it hit the press, but the scaffolding behind it hasn't been stress-tested yet.
Brian Reed: So walk me through the actual thing that's missing. Because to me, the biggest hole isn't the measurement slice — it's that nobody got healthier. Like, in any documented way.
Eliza Ward: No clinical endpoints. None. No diabetes rates, no cardiovascular events, nothing connecting the fat reduction to actual disease outcomes. The trial measured the fat itself. That's it. The biological logic — visceral fat drives inflammation, insulin resistance, the whole metabolic cascade — that logic is sound. But CBL-0204 and CBL-0205 didn't test whether removing that fat at L2-to-L3 translates to a healthier patient. Those are genuinely different claims.
Brian Reed: Okay, so picture the 52-year-old woman, BMI 26, reads the October 13 headlines, walks into her annual physical — what can her doctor actually do with this?
Eliza Ward: Nothing, today. CBL-514 isn't approved. Her doctor can't order an L2-to-L3 MRI as routine screening. And there's no outcome data connecting her fat distribution to her specific disease risk via this drug. Phase 3 trials haven't happened. And that's actually the thread worth pulling — what this would mean for clinical guidelines and how it stacks against GLP-1s if it ever does get there. But that's a different question than what the phase 2 data actually shows.
Brian Reed: And GLP-1s already get there, right? Like semaglutide is already reducing visceral fat — so what's the actual gap CBL-514 is filling?
Eliza Ward: That's — wait, this is the thing that actually reframed it for me. Semaglutide hits visceral fat preferentially, harder than subcutaneous. That's in the literature. But we call it a weight-loss drug because the scale moves. CBL-514 doesn't move the scale, so suddenly the framing shifts to 'metabolically targeted.' Same underlying biology. Different narrative because of one instrument.
Brian Reed: The scale is doing the labeling.
Eliza Ward: Exactly. And the 2026 meta-analysis in Journal of Thoracic Disease — epicardial adipose tissue, which is a visceral fat depot, linked independently to adverse outcomes in acute myocardial infarction patients — that's not a weight story. That's a fat-location story. The biology has been saying this for years. The framing just kept chasing the scale.
Brian Reed: Okay, that one actually shifts something for me — because if the framing has been set by the scale all along, not the biology, then redefining success as visceral fat reduction changes who even counts as a treatment candidate.
Eliza Ward: That's the clinical guidelines problem. Imagine a cardiologist reviewing a 58-year-old male patient post-stent, BMI 24, no obesity flag — he never gets referred for metabolic intervention. But if his epicardial adipose tissue is elevated, the Journal of Thoracic Disease data says he's already at elevated risk. The treatment population just got larger and we don't have the infrastructure to find them.
Brian Reed: And insurers are paying for outcomes, not fat redistribution. So who covers the MRI that identifies him?
Eliza Ward: Nobody, right now. And that's — I mean, the CBL-514 trials injected up to 600 mg per treatment, every four weeks, directly into abdominal tissue. That's a highly specific delivery mechanism. It is not a pill. It is not a lifestyle program. Insurers need outcome data before they reimburse that, and we don't have it yet. So the question isn't just whether the biology holds — it's whether the evidence infrastructure catches up fast enough to matter.
Brian Reed: And that's — I mean, that's the thing I'm left holding. If phase 3 eventually shows CBL-514 actually lowers diabetes incidence, actually cuts cardiovascular events — that's not just a drug approval. That rewrites who gets measured, who gets treated. Should primary care systems be screening visceral fat distribution in people with a BMI of 26 who look completely fine on paper? And does any health system anywhere have the infrastructure to do that at scale?
Eliza Ward: I don't think anyone's answered that. Not even close.
Brian Reed: No. And I'm not sure phase 3 can answer it either — even if the outcome data comes back clean.
